Results 201 to 210 of about 116,176 (290)
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2 [PDF]
Bartlett, Nancy L, et al.,
core +1 more source
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang +18 more
wiley +1 more source
Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort. [PDF]
Munir T +10 more
europepmc +1 more source
B Cell Maturation in Chronic Lymphocytic Leukemia
K. Pfeffer, C. Nerl, D. Kabelitz
openaire +1 more source
Background and Purpose Bruton tyrosine kinase (Btk) is essential for B cell function. Its role in myeloid cells is less understood. Greater insights into Btk significance in myeloid cells are needed to evaluate its potential as a therapeutic target during the effector phase of antibody‐induced autoimmune diseases, where inhibiting autoantibody ...
Henning Olbrich +7 more
wiley +1 more source
Abstract Background and Purpose Spleen tyrosine kinase (SYK) has broad biological functions in inflammation and immunity. The orally administered SYK inhibitor BI 894416 was investigated in a single‐rising‐dose Phase I study in healthy volunteers and in a combined single‐ and multiple‐rising‐dose Phase Ib study in patients with mild asthma ...
Saskia Carstensen‐Aurèche +8 more
wiley +1 more source
Role of microRNAs in hematological malignancies research: A bibliometric analysis. [PDF]
Abdullah SM.
europepmc +1 more source
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL [PDF]
Bartlett, Nancy L.
core +1 more source

